We also performed similar analyses in rodent drug treatment signatures. We had access to unpublished data (PFS) from RNA sequencing performed on mice previously treated with haloperidol. A brief description of data generation is as follows. All experimental procedures were randomized to minimize batch artifacts, including assignment of mice to receive haloperidol (HAL) or placebo (PLA), home cage, order of dissection, RNA extraction, and assay batch. Male C57BL/6J mice were chronically treated with HAL (N = 16) or PLA (N = 12) for 30 days, and the striata were dissected (15–17 mice per treatment group). All individual striatal samples were assayed using RNA-seq. Quality control and analysis for all data types conformed to those developed in our prior publications19. We considered differential expression at FDR q < 0.05 as the criterion for inclusion in the set of genes we considered to be affected by the drug.
